查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1433529

先进治疗药物 CDMO 市场规模、份额、趋势分析报告：按产品、阶段、适应症、地区、细分市场预测，2024-2030 年

Advanced Therapy Medicinal Products CDMO Market Size, Share & Trends Analysis Report By Product (Gene Therapy, Cell Therapy), By Phase, By Indication, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

先进疗法 CDMO 市场成长与趋势：

Grand View Research, Inc.的最新报告显示，到2030年，全球先进疗法CDMO市场规模预计将达到188亿美元。

预计2024年至2030年市场复合年增长率为18.92%。这是因为先进治疗药物的临床试验数量不断增加，研究人员对先进治疗益处的认识不断提高，正在推动先进治疗药物 (ATMP) CDMO 市场的成长。组织工程受益于近年来的技术发展。使用这种技术可以替代或恢復受损组织和器官的功能。同样，基因和细胞疗法正在吸引更多患者来治疗全球范围内患病率不断上升的罕见疾病。

随着对强大疾病治疗疗法的需求增加，领先公司正在专注于研究和开发在基因组层级上针对疾病原因的有效基因疗法。根据ASGCT的数据，美国管道计画（I-III期试验）中的细胞和基因治疗药物数量从2021年的483种增加到2022年的529种。此外，FDA 持续透过多项产品製造政策支持基因治疗领域的创新。 2020年1月，FDA发布了基因治疗产品安全高效生产和临床开发的六项最终指南。

此外，旨在向公众宣传这些产品的好处的倡议正在推动人们对 ATMP 治疗方案的认识，从而增加先进治疗方法的采用并刺激 CDMO 的市场成长。我正在申请。例如，细胞和基因医学再生医学基金会联盟强调再生医学的临床和社会效益，并优先努力透过教育计画提高公众意识。

与新产品发布相关的临床试验活动的增加创造了市场成长机会。截至2022年，有1,451个ATMP处于临床前阶段，535个产品正在进行第一阶段至第三阶段试验。自 2020 年 8 月以来，EMA 已额外核准了其中 6 个 ATMP，预计到 2023 年还将核准另外 5 个。在英国，2021 年约有 168 项先进治疗医学临床试验正在进行，比前一年的 154 项增加了 9%。 2021年一期临床试验增加了32%，显示从实验药物到首次人体临床试验的重大转变。

同时，主要企业正在采取各种策略措施来推出新产品，预计将推动市场成长。例如，2021 年 3 月，CureVac NV 与 Celonic Group 签订了合作伙伴协议，生产 CVnCoV，即 CureVac 的基于 mRNA 的 COVID-19 候选疫苗。 CureVac 的 COVID-19 候选疫苗将在 Celonic 位于德国海德堡的 ATMP 和生技药品商业生产工厂生产。根据商业供应协议的条款，Celonic 的工厂将能够生产超过 1 亿剂 CVnCoV。

先进疗法 CDMO 市场报告亮点：

  • 基因治疗领域将占最大份额，2023年将超过49.2%。资金的增加和基因治疗临床试验数量的增加正在推动基因治疗领域的需求。
  • 预计细胞治疗领域将在预测期内呈现良好的成长。细胞治疗领域透过整合新的细胞类型不断发展，为公司提高市场地位提供了充足的机会。
  • 2023 年，肿瘤学领域占销售额的最大份额。该行业的主导地位是由于疾病负担、主要企业的策略性倡议以及用于治疗各种癌症适应症的先进治疗方法的可用性。
  • 由于研发活动的活性化和先进疗法的人体试验数量的增加，I 期细分市场将在 2023 年占据市场主导地位。
  • 2023年，北美以49.0%的市场占有率主导市场。这可以归因于外包活动的增加和对先进治疗的认识的提高。
  • 由于对新型 ATMP 的需求增加以及开发新型治疗方法的研发活动活性化，预计亚太地区在预测期内将以最快的复合年增长率成长。

目录

第一章调查方法与范围

第二章先进疗法 CDMO 市场：执行摘要

  • 市场概述
  • 产品简介
  • 阶段简介
  • 显示简介
  • 竞争形势概览

第 3 章 先进疗法 CDMO 市场变数、趋势与范围

  • 市场区隔和范围
  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
  • 市场驱动因素分析
    • ATMP临床试验数量增加
    • 外包活动增加
    • 提高治疗意识
  • 市场限制因素分析
    • 严格的监管核准
    • 外包成本高
  • 先进的治疗 CDMO 市场分析工具
    • 产业分析-波特五力分析
    • PESTLE分析

第四章 先进治疗药物CDMO市场：产品预估及趋势分析

  • 2023年及2030年产品市场占有率
  • 细分仪表板
  • 全球先进疗法 CDMO 市场（依产品前景）
  • 2018年至2030年市场规模、预测与趋势分析如下
    • 基因治疗
    • 细胞疗法
    • 透过组织工程
    • 其他的

第五章先进治疗药物 CDMO 市场：阶段估计与趋势分析

  • 2023年及2030年阶段市场占有率
  • 细分仪表板
  • 全球先进疗法 CDMO 市场，分阶段展望
  • 2018年至2030年市场规模、预测与趋势分析如下
    • 第一阶段
    • 第二阶段
    • 第三阶段
    • 第四阶段

第六章 先进治疗药物CDMO市场：适应症估计与趋势分析

  • 2023年及2030年指示市场占有率
  • 细分仪表板
  • 全球先进治疗药物 CDMO 市场，按适应症展望
  • 2018年至2030年市场规模、预测与趋势分析如下
    • 肿瘤学
    • 心臟病学
    • 中枢神经系统
    • 肌肉骨骼系统
    • 感染疾病
    • 皮肤科
    • 内分泌、代谢、遗传学
    • 免疫学和发炎
    • 眼科
    • 血液学
    • 消化内科
    • 其他的

第七章 区域业务分析

  • 2023 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 全球区域市场概况
  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 西班牙
    • 法国
    • 义大利
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 泰国
    • 澳洲
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争形势

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商形势
    • List Of Key Distributors And Channel Partners
    • Key Customers
    • Key Company Market Share Analysis, 2023
    • CELONIC Group
    • Bio Elpida
    • Rentschler Biopharma SE
    • AGC Biologics
    • Catalent, Inc.
    • Lonza
    • Wuxi Advanced Therapies
    • Minaris Regenerative Medicine
    • Patheon, Inc.
    • CGT Catapult
Product Code: GVR-4-68039-676-6

Advanced Therapy Medicinal Products CDMO Market Growth & Trends:

The global advanced therapy medicinal products CDMO market size is expected to reach USD 18.8 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to register a CAGR of 18.92% from 2024 to 2030, owing to rising clinical trials for advanced therapy medicinal products and the increasing awareness among researchers about the benefits of advanced therapies, driving the advanced therapy medicinal products (ATMP) CDMO market growth. Tissue engineering has greatly benefited in recent years from technological development. The damaged tissues and organ function are replaced or restored using this technique. Similarly, gene and cell therapy are attracting a lot of patients for the treatment of rare diseases, whose incidence is rising globally.

With rising demand for robust disease treatment therapies, key players have focused their efforts to ramp up research and development for effective gene therapies that target the cause of disorder at a genomic level. According to ASGCT, the number of cell and gene therapies in the U.S. pipeline programs (phase I-III trials) increased from 483 in 2021 to 529 in 2022. Furthermore, the FDA delivers constant support for innovations in the gene therapy field via a number of policies with regard to product manufacturing. In January 2020, the agency released six final guidelines on the manufacturing and clinical development of safe & efficient gene therapy products.

Moreover, awareness about ATMP treatment options is being driven by initiatives aimed at informing the public about the benefits of these products, which, in turn, is leading to increased adoption of advanced therapies and fueling market growth for CDMOs. For instance, Alliance for Regenerative Medicine Foundation for Cell and Gene Medicine prioritizes activities for increasing public awareness through educational programs, underlining the clinical & societal benefits of regenerative medicine.

Increasing clinical trial activity along with new product launches generates growth opportunities for the market. As of 2022, there are 1451 ATMPs in preclinical stages and 535 are being studied in Phase 1 to 3 studies. Since August 2020, EMA has approved six of these additional ATMPs, and five more will be approved by 2023. In the UK, there were approximately 168 advanced therapy medicinal product trials underway in 2021, up from the 154 studies reported the year before, which is a 9% increase. 2021 saw a 32% increase in phase 1 trials, indicating a significant shift from experimental medicines to first-in-human studies.

On the other hand, key players are undertaking various strategic initiatives to introduce novel products, which is expected to propel market growth. For instance, in March 2021, CureVac N.V. signed a partnership agreement with Celonic Group, engaged in the manufacture of CVnCoV, CureVac's mRNA-based COVID-19 vaccine candidate. CureVac's COVID-19 vaccine candidate is manufactured at Celonic's commercial manufacturing unit for ATMPs and biologics in Heidelberg, Germany. Under the terms of the commercial supply agreement, the Celonic facility could produce over 100 million doses of CVnCoV.

Advanced Therapy Medicinal Products CDMO Market Report Highlights:

  • The gene therapy segment held the largest share of over 49.2% in 2023. Increase in financial support and rise in number of clinical trials for gene therapies are driving demand for the gene therapy segment.
  • The cell therapy segment is expected to show lucrative growth over the forecast period. The field of cellular therapeutics is constantly advancing with inclusion of new cell types, which, in turn, provides ample opportunities for companies to enhance their market positions.
  • The oncology segment accounted for the largest revenue share in 2023. The segment's dominance is attributed to disease burden, strategic initiatives undertaken by key players, and availability of advanced therapies used for treating various cancer indications.
  • The phase I segment dominated the market in 2023 due to growing R&D activities and increasing number of human trials for advanced therapies.
  • North America dominated the overall market share of 49.0% in 2023. This can be attributed to increasing outsourcing activities and rising awareness about advanced therapy.
  • The Asia Pacific region is expected to grow at the fastest CAGR over the forecast period due to the increasing demand for novel ATMPs and rising R&D activities to develop novel therapies.

Table of Contents

Chapter 1. Methodology And Scope

  • 1.1. Market Segmentation And Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Product Segment
      • 1.1.1.2. Phase Segment
      • 1.1.1.3. Indication Segment
  • 1.2. Regional Scope
  • 1.3. Estimates And Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List Of Primary Sources
  • 1.11. List Of Abbreviations

Chapter 2. Advanced Therapy Medicinal Products CDMO Market: Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Products Snapshots
  • 2.3. Phase Snapshots
  • 2.4. Indication Snapshot
  • 2.5. Competitive Landscape Snapshot

Chapter 3. Advanced Therapy Medicinal Products CDMO Market Variables, Trends, & Scope

  • 3.1. Market Segmentation And Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers Analysis
    • 3.4.1. Rising number of clinical trials for ATMPs
    • 3.4.2. Increasing outsourcing activities
    • 3.4.3. Growing awareness of the treatment
  • 3.5. Market Restraint Analysis
    • 3.5.1. Stringent regulatory approvals
    • 3.5.2. High cost of outsourcing
  • 3.6. Advanced Therapy Medicinal Products CDMO Market Analysis Tools
    • 3.6.1. Industry Analysis - Porter's
      • 3.6.1.1. Supplier Power
      • 3.6.1.2. Buyer Power
      • 3.6.1.3. Substitution Threat
      • 3.6.1.4. Threat Of New Entrant
      • 3.6.1.5. Competitive Rivalry
    • 3.6.2. PESTLE Analysis
      • 3.6.2.1. Political Landscape
      • 3.6.2.2. Technological Landscape
      • 3.6.2.3. Economic Landscape

Chapter 4. Advanced Therapy Medicinal Products CDMO: Products Estimates & Trend Analysis

  • 4.1. Product Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Advanced Therapy Medicinal Products CDMO Market, By Product Outlook
  • 4.4. Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Following
    • 4.4.1. Gene Therapy
      • 4.4.1.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 4.4.2. Cell Therapy
      • 4.4.2.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 4.4.3. Tissue Engineered
      • 4.4.3.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 4.4.4. Others
      • 4.4.4.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)

Chapter 5. Advanced Therapy Medicinal Products CDMO: Phase Estimates & Trend Analysis

  • 5.1. Phase Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Advanced Therapy Medicinal Products CDMO Market, By Phase Outlook
  • 5.4. Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Following
    • 5.4.1. Phase I
      • 5.4.1.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 5.4.2. Phase II
      • 5.4.2.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 5.4.3. Phase III
      • 5.4.3.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 5.4.4. Phase IV
      • 5.4.4.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)

Chapter 6. Advanced Therapy Medicinal Products CDMO: Indication Estimates & Trend Analysis

  • 6.1. Indication Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Advanced Therapy Medicinal Products CDMO Market, By Indication Outlook
  • 6.4. Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Following
    • 6.4.1. Oncology
      • 6.4.1.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 6.4.2. Cardiology
      • 6.4.2.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 6.4.3. Central Nervous System
      • 6.4.3.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 6.4.4. Musculoskeletal
      • 6.4.4.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 6.4.5. Infectious Disease
      • 6.4.5.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 6.4.6. Dermatology
      • 6.4.6.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 6.4.7. Endocrine, Metabolic, Genetic
      • 6.4.7.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 6.4.8. Immunology & Inflammation
      • 6.4.8.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 6.4.9. Ophthalmology
      • 6.4.9.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 6.4.10. Hematology
      • 6.4.10.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 6.4.11. Gastroenterology
      • 6.4.11.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 6.4.12. Others
      • 6.4.12.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)

Chapter 7. Regional Business Analysis

  • 7.1. Regional Market Share Analysis, 2023 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Marker Size, & Forecasts Trend Analysis, 2018 To 2030:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key Country Dynamics
      • 7.5.1.2. Competitive Scenario
      • 7.5.1.3. Regulatory Framework
      • 7.5.1.4. U.S. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Canada Market Estimates And Forecasts, 2018 To 2030 (USD Million)
  • 7.6. Europe
    • 7.6.1. UK
      • 7.6.1.1. Key Country Dynamics
      • 7.6.1.2. Competitive Scenario
      • 7.6.1.3. Regulatory Framework
      • 7.6.1.4. UK Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 7.6.2. Germany
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Germany Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 7.6.3. Spain
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Spain Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 7.6.4. France
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. France Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 7.6.5. Italy
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Competitive Scenario
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Italy Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 7.6.6. Denmark
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Competitive Scenario
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Denmark Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 7.6.7. Sweden
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Competitive Scenario
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Sweden Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 7.6.8. Norway
      • 7.6.8.1. Key Country Dynamics
      • 7.6.8.2. Competitive Scenario
      • 7.6.8.3. Regulatory Framework
      • 7.6.8.4. Norway Market Estimates And Forecasts, 2018 To 2030 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key Country Dynamics
      • 7.7.1.2. Competitive Scenario
      • 7.7.1.3. Regulatory Framework
      • 7.7.1.4. Japan Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 7.7.2. China
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. China Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 7.7.3. India
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. India Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 7.7.4. South Korea
      • 7.7.4.1. Key Country Dynamics
      • 7.7.4.2. Competitive Scenario
      • 7.7.4.3. Regulatory Framework
      • 7.7.4.4. South Korea Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 7.7.5. Thailand
      • 7.7.5.1. Key Country Dynamics
      • 7.7.5.2. Competitive Scenario
      • 7.7.5.3. Regulatory Framework
      • 7.7.5.4. Thailand Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 7.7.6. Australia
      • 7.7.6.1. Key Country Dynamics
      • 7.7.6.2. Competitive Scenario
      • 7.7.6.3. Regulatory Framework
      • 7.7.6.4. Australia Market Estimates And Forecasts, 2018 To 2030 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key Country Dynamics
      • 7.8.1.2. Competitive Scenario
      • 7.8.1.3. Regulatory Framework
      • 7.8.1.4. Brazil Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 7.8.2. Mexico
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Competitive Scenario
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Mexico Advanced Therapy Medicinal Products CDMO Market, 2018 - 2030 (USD Million)
    • 7.8.3. Argentina
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Competitive Scenario
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Argentina Market Estimates And Forecasts, 2018 To 2030 (USD Million)
  • 7.9. MEA
    • 7.9.1. MEA Advanced Therapy Medicinal Products CDMO Market, 2018 - 2030 (USD Million)
    • 7.9.2. South Africa
      • 7.9.2.1. Key Country Dynamics
      • 7.9.2.2. Competitive Scenario
      • 7.9.2.3. Regulatory Framework
      • 7.9.2.4. South Africa Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 7.9.3. Saudi Arabia
      • 7.9.3.1. Key Country Dynamics
      • 7.9.3.2. Competitive Scenario
      • 7.9.3.3. Regulatory Framework
      • 7.9.3.4. Saudi Arabia Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 7.9.4. UAE
      • 7.9.4.1. Key Country Dynamics
      • 7.9.4.2. Competitive Scenario
      • 7.9.4.3. Regulatory Framework
      • 7.9.4.4. UAE Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 7.9.5. Kuwait
      • 7.9.5.1. Key Country Dynamics
      • 7.9.5.2. Competitive Scenario
      • 7.9.5.3. Regulatory Framework
      • 7.9.5.4. Kuwait Market Estimates And Forecasts, 2018 To 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company /Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List Of Key Distributors And Channel Partners
    • 8.3.2. Key Customers
    • 8.3.3. Key Company Market Share Analysis, 2023
    • 8.3.4. CELONIC Group
      • 8.3.4.1. Overview
      • 8.3.4.2. Financial Performance
      • 8.3.4.3. Product Benchmarking
      • 8.3.4.4. Strategic Initiatives
    • 8.3.5. Bio Elpida
      • 8.3.5.1. Overview
      • 8.3.5.2. Financial Performance
      • 8.3.5.3. Product Benchmarking
      • 8.3.5.4. Strategic Initiatives
    • 8.3.6. Rentschler Biopharma SE
      • 8.3.6.1. Overview
      • 8.3.6.2. Financial Performance
      • 8.3.6.3. Product Benchmarking
      • 8.3.6.4. Strategic Initiatives
    • 8.3.7. AGC Biologics
      • 8.3.7.1. Overview
      • 8.3.7.2. Financial Performance
      • 8.3.7.3. Product Benchmarking
      • 8.3.7.4. Strategic Initiatives
    • 8.3.8. Catalent, Inc.
      • 8.3.8.1. Overview
      • 8.3.8.2. Financial Performance
      • 8.3.8.3. Product Benchmarking
      • 8.3.8.4. Strategic Initiatives
    • 8.3.9. Lonza
      • 8.3.9.1. Overview
      • 8.3.9.2. Financial Performance
      • 8.3.9.3. Product Benchmarking
      • 8.3.9.4. Strategic Initiatives
    • 8.3.10. Wuxi Advanced Therapies
      • 8.3.10.1. Overview
      • 8.3.10.2. Financial Performance
      • 8.3.10.3. Product Benchmarking
      • 8.3.10.4. Strategic Initiatives
    • 8.3.11. Minaris Regenerative Medicine
      • 8.3.11.1. Overview
      • 8.3.11.2. Financial Performance
      • 8.3.11.3. Product Benchmarking
      • 8.3.11.4. Strategic Initiatives
    • 8.3.12. Patheon, Inc.
      • 8.3.12.1. Overview
      • 8.3.12.2. Financial Performance
      • 8.3.12.3. Product Benchmarking
      • 8.3.12.4. Strategic Initiatives
    • 8.3.13. CGT Catapult
      • 8.3.13.1. Overview
      • 8.3.13.2. Financial Performance
      • 8.3.13.3. Product Benchmarking
      • 8.3.13.4. Strategic Initiatives

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America Advanced Therapy Medicinal Products CDMO Market, by Region, 2018 - 2030 (USD Million)
  • Table 3 North America Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 4 North America Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 5 North America Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 6 U.S. Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 7 U.S. Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 8 U.S. Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 9 Canada Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 10 Canada Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 11 Canada Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 12 Europe Advanced Therapy Medicinal Products CDMO Market, by Region, 2018 - 2030 (USD Million)
  • Table 13 Europe Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 14 Europe Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 15 Europe Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 16 UK Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 17 UK Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 18 UK Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 19 Germany Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 20 Germany Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 21 Germany Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 22 France Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 23 France Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 24 France Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 25 Italy Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 26 Italy Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 27 Italy Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 28 Spain Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 29 Spain Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 30 Spain Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 31 Sweden Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 32 Sweden Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 33 Sweden Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 34 Norway Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 35 Norway Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 36 Norway Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 37 Denmark Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 38 Denmark Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 39 Denmark Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific Advanced Therapy Medicinal Products CDMO Market, by Region, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 44 Japan Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 45 Japan Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 46 Japan Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 47 China Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 48 China Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 49 China Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 50 India Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 51 India Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 52 India Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 53 Australia Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 54 Australia Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 55 Australia Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 56 South Korea Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 57 South Korea Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 58 South Korea Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 59 Thailand Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 60 Thailand Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 61 Thailand Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 62 Latin America Advanced Therapy Medicinal Products CDMO Market, by Region, 2018 - 2030 (USD Million)
  • Table 63 Latin America Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 64 Latin America Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 65 Latin America Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 66 Brazil Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 67 Brazil Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 68 Brazil Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 69 Argentina Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 70 Argentina Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 71 Argentina Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 72 Mexico Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 73 Mexico Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 74 Mexico Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 75 MEA Advanced Therapy Medicinal Products CDMO Market, by Region, 2018 - 2030 (USD Million)
  • Table 76 MEA Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 77 MEA Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 78 MEA Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 79 South Africa Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 80 South Africa Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 81 South Africa Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 85 UAE Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 86 UAE Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 87 UAE Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 88 Kuwait Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 89 Kuwait Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 90 Kuwait Advanced Therapy Medicinal Products CDMO Market, Test type, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Data Triangulation Techniques
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Primary Interviews In North America
  • Fig. 5 Primary Interviews In Europe
  • Fig. 6 Primary Interviews In Asia Pacific
  • Fig. 7 Primary Interviews In Latin America
  • Fig. 8 Primary Interviews In Middle East & Africa
  • Fig. 9 Market Research Approaches
  • Fig. 10 Value-Chain-Based Sizing & Forecasting
  • Fig. 11 QFD Modeling For Market Share Assessment
  • Fig. 12 Market Formulation & Validation
  • Fig. 13 Advanced Therapy Medicinal Products CDMO Market: Market Outlook
  • Fig. 14 Advanced Therapy Medicinal Products CDMO Competitive Insights
  • Fig. 15 Parent Market Outlook
  • Fig. 16 Related/Ancillary Market Outlook
  • Fig. 17 Penetration And Growth Prospect Mapping
  • Fig. 18 Industry Value Chain Analysis
  • Fig. 19 Advanced Therapy Medicinal Products CDMO Market Driver Impact
  • Fig. 20 Advanced Therapy Medicinal Products CDMO Market Restraint Impact
  • Fig. 21 Advanced Therapy Medicinal Products CDMO Market Strategic Initiatives Analysis
  • Fig. 22 Advanced Therapy Medicinal Products CDMO Market: Product Movement Analysis
  • Fig. 23 Advanced Therapy Medicinal Products CDMO Market: Product Outlook And Key Takeaways
  • Fig. 24 Gene Therapy Market Estimates And Forecast, 2018 - 2030
  • Fig. 25 Cell Therapy Estimates And Forecast, 2018 - 2030
  • Fig. 26 Tissue Engineered Estimates And Forecast, 2018 - 2030
  • Fig. 27 Others Estimates And Forecast, 2018 - 2030
  • Fig. 28 Advanced Therapy Medicinal Products CDMO Market: Phase Movement Analysis
  • Fig. 29 Advanced Therapy Medicinal Products CDMO Market: Phase Outlook And Key Takeaways
  • Fig. 30 Phase I Market Estimates And Forecasts, 2018 - 2030
  • Fig. 31 Phase II Market Estimates And Forecasts, 2018 - 2030
  • Fig. 32 Phase III Market Estimates And Forecasts, 2018 - 2030
  • Fig. 33 Phase IV Market Estimates And Forecasts, 2018 - 2030
  • Fig. 34 Advanced Therapy Medicinal Products CDMO Market: Indication Movement Analysis
  • Fig. 35 Advanced Therapy Medicinal Products CDMO Market: Indication Outlook And Key Takeaways
  • Fig. 36 Oncology Market Estimates And Forecasts, 2018 - 2030
  • Fig. 37 Cardiology Market Estimates And Forecasts,2018 - 2030
  • Fig. 38 Central Nervous System Estimates And Forecasts, 2018 - 2030
  • Fig. 39 Musculoskeletal Estimates And Forecasts, 2018 - 2030
  • Fig. 40 Infectious Disease Estimates And Forecasts, 2018 - 2030
  • Fig. 41 Dermatology Estimates And Forecasts, 2018 - 2030
  • Fig. 42 Others Estimates And Forecasts, 2018 - 2030
  • Fig. 43 Global Advanced Therapy Medicinal Products CDMO Market: Regional Movement Analysis
  • Fig. 44 Global Advanced Therapy Medicinal Products CDMO Market: Regional Outlook And Key Takeaways
  • Fig. 45 Global Advanced Therapy Medicinal Products CDMO Market Share And Leading Players
  • Fig. 46 North America Market Share And Leading Players
  • Fig. 47 Europe Market Share And Leading Players
  • Fig. 48 Asia Pacific Market Share And Leading Players
  • Fig. 49 Latin America Market Share And Leading Players
  • Fig. 50 Middle East & Africa Market Share And Leading Players
  • Fig. 51 North America: SWOT
  • Fig. 52 Europe SWOT
  • Fig. 53 Asia Pacific SWOT
  • Fig. 54 Latin America SWOT
  • Fig. 55 MEA SWOT
  • Fig. 56 North America
  • Fig. 57 North America Market Estimates And Forecasts, 2018 - 2030
  • Fig. 58 U.S.
  • Fig. 59 U.S. Market Estimates And Forecasts, 2018 - 2030
  • Fig. 60 Canada
  • Fig. 61 Canada Market Estimates And Forecasts, 2018 - 2030
  • Fig. 62 Europe
  • Fig. 63 Europe Market Estimates And Forecasts, 2018 - 2030
  • Fig. 64 UK
  • Fig. 65 UK Market Estimates And Forecasts, 2018 - 2030
  • Fig. 66 Germany
  • Fig. 67 Germany Market Estimates And Forecasts, 2018 - 2030
  • Fig. 68 France
  • Fig. 69 France Market Estimates And Forecasts, 2018 - 2030
  • Fig. 70 Italy
  • Fig. 71 Italy Market Estimates And Forecasts, 2018 - 2030
  • Fig. 72 Spain
  • Fig. 73 Spain Market Estimates And Forecasts, 2018 - 2030
  • Fig. 74 Denmark
  • Fig. 75 Denmark Market Estimates And Forecasts, 2018 - 2030
  • Fig. 76 Sweden
  • Fig. 77 Sweden Market Estimates And Forecasts, 2018 - 2030
  • Fig. 78 Norway
  • Fig. 79 Norway Market Estimates And Forecasts, 2018 - 2030
  • Fig. 80 Asia Pacific
  • Fig. 81 Asia Pacific Market Estimates And Forecasts, 2018 - 2030
  • Fig. 82 China
  • Fig. 83 China Market Estimates And Forecasts, 2018 - 2030
  • Fig. 84 Japan
  • Fig. 85 Japan Market Estimates And Forecasts, 2018 - 2030
  • Fig. 86 India
  • Fig. 87 India Market Estimates And Forecasts, 2018 - 2030
  • Fig. 88 Thailand
  • Fig. 89 Thailand Market Estimates And Forecasts, 2018 - 2030
  • Fig. 90 South Korea
  • Fig. 91 South Korea Market Estimates And Forecasts, 2018 - 2030
  • Fig. 92 Australia
  • Fig. 93 Australia Market Estimates And Forecasts, 2018 - 2030
  • Fig. 94 Latin America
  • Fig. 95 Latin America Market Estimates And Forecasts, 2018 - 2030
  • Fig. 96 Brazil
  • Fig. 97 Brazil Market Estimates And Forecasts, 2018 - 2030
  • Fig. 98 Mexico
  • Fig. 99 Mexico Market Estimates And Forecasts, 2018 - 2030
  • Fig. 100 Argentina
  • Fig. 101 Argentina Market Estimates And Forecasts, 2018 - 2030
  • Fig. 102 Middle East And Africa
  • Fig. 103 Middle East And Africa Market Estimates And Forecasts, 2018 - 2030
  • Fig. 104 South Africa
  • Fig. 105 South Africa Market Estimates And Forecasts, 2018 - 2030
  • Fig. 106 Saudi Arabia
  • Fig. 107 Saudi Arabia Market Estimates And Forecasts, 2018 - 2030
  • Fig. 108 UAE
  • Fig. 109 UAE Market Estimates And Forecasts, 2018 - 2030
  • Fig. 110 Kuwait
  • Fig. 111 Kuwait Market Estimates And Forecasts, 2018 - 2030
  • Fig. 112 Market Share Of Key Market Players - Advanced Therapy Medicinal Products CDMO Market